Day One Biopharmaceuticals Stock Jumps on Renewed M&A Rumors
Day One Biopharmaceuticals shares surge 26% to $12.62 amid fresh speculation of a potential buyout.
/ 2 items
Day One Biopharmaceuticals shares surge 26% to $12.62 amid fresh speculation of a potential buyout.
Day One is acquiring Mersana Therapeutics for up to $285 million to gain Emi-Le, a promising new drug candidate for adenoid cystic carcinoma, a cancer with few treatment options.